These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 38362864)

  • 1. The role of the microbiome in liver disease.
    Schöler D; Schnabl B
    Curr Opin Gastroenterol; 2024 May; 40(3):134-142. PubMed ID: 38362864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Benedé-Ubieto R; Cubero FJ; Nevzorova YA
    Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promises of microbiome-based therapies.
    Bajaj JS; Ng SC; Schnabl B
    J Hepatol; 2022 Jun; 76(6):1379-1391. PubMed ID: 35589257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.
    Park IG; Yoon SJ; Won SM; Oh KK; Hyun JY; Suk KT; Lee U
    Sci Rep; 2024 Jul; 14(1):16122. PubMed ID: 38997279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease.
    Ranjbarian T; Schnabl B
    Semin Liver Dis; 2023 Aug; 43(3):311-322. PubMed ID: 37527781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiome as a therapeutic target in alcohol-related liver disease.
    Sarin SK; Pande A; Schnabl B
    J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
    Hong M; Han DH; Hong J; Kim DJ; Suk KT
    Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut Bacteria in Alcohol-Associated Liver Disease.
    Yang Y; Schnabl B
    Clin Liver Dis; 2024 Nov; 28(4):663-679. PubMed ID: 39362714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
    J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
    Das BK
    APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
    Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
    Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
    Leclercq S; de Timary P; Stärkel P
    Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.
    Koning M; Herrema H; Nieuwdorp M; Meijnikman AS
    Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.
    Hyun JY; Kim SK; Yoon SJ; Lee SB; Jeong JJ; Gupta H; Sharma SP; Oh KK; Won SM; Kwon GH; Cha MG; Kim DJ; Ganesan R; Suk KT
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol or Gut Microbiota: Who Is the Guilty?
    Meroni M; Longo M; Dongiovanni P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutritional Interventions, Probiotics, Synbiotics and Fecal Microbiota Transplantation in Steatotic Liver Disease : Pediatric Fatty Liver and Probiotics.
    Nicastro E; D'Antiga L
    Adv Exp Med Biol; 2024; 1449():113-133. PubMed ID: 39060734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment.
    Zhang R; Yan Z; Zhong H; Luo R; Liu W; Xiong S; Liu Q; Liu M
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38967596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Popov J; Despot T; Avelar Rodriguez D; Khan I; Mech E; Khan M; Bojadzija M; Pai N
    Nutrients; 2024 May; 16(11):. PubMed ID: 38892602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.